Overview
Pancreatic cancer is one of the most challenging malignancies in oncology — often diagnosed at an advanced stage, with limited treatment options and historically poor prognosis. Yet for patients who can access the world's most experienced pancreatic cancer surgeons and the most innovative treatment protocols, outcomes can be significantly better than the global average. Shanghai is home to China's foremost pancreatic cancer center, led by a surgeon whose individualized treatment approach has extended patient survival by 40% compared to conventional standards.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top pancreatic cancer specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Pancreatic Cancer
What Is Pancreatic Cancer?
Pancreatic cancer develops in the tissues of the pancreas — a gland located behind the stomach that produces digestive enzymes and hormones including insulin. The most common type is pancreatic ductal adenocarcinoma (PDAC), which accounts for approximately 90% of cases. Pancreatic cancer is the seventh leading cause of cancer death worldwide, with a global 5-year survival rate of less than 12%.
The poor prognosis is largely attributable to late diagnosis — most patients present with locally advanced or metastatic disease — and the aggressive biology of the tumor. However, for patients with resectable disease who are treated at high-volume specialist centers, 5-year survival rates can reach 20–30% or higher.
Common Symptoms
- Painless jaundice (yellowing of the skin and eyes) — often the first sign of pancreatic head cancer
- Upper abdominal or back pain
- Unexplained weight loss and loss of appetite
- New-onset diabetes or worsening of existing diabetes
- Nausea and vomiting
- Fatigue
- Light-colored stools and dark urine
Risk Factors
- Age over 60
- Smoking (doubles the risk)
- Chronic pancreatitis
- Diabetes mellitus (particularly new-onset)
- Obesity and sedentary lifestyle
- Family history of pancreatic cancer
- Hereditary syndromes (BRCA1/2, Lynch syndrome, familial atypical mole-melanoma syndrome)
Diagnosis & Staging
Accurate staging is critical for determining resectability and treatment strategy. At Shanghai's leading centers, the standard workup includes:
- CT scan (pancreatic protocol) — the gold standard for pancreatic cancer staging and resectability assessment
- MRI / MRCP — biliary and pancreatic duct assessment
- Endoscopic ultrasound (EUS) with fine-needle aspiration (FNA) — tissue diagnosis and local staging
- PET-CT — selected cases for distant metastasis assessment
- CA19-9 and CEA — tumor markers for diagnosis and monitoring
- Molecular profiling — BRCA1/2, KRAS, MSI/MMR, NTRK for targeted therapy and clinical trial eligibility
- Multidisciplinary resectability assessment — formal MDT review to classify as resectable, borderline resectable, locally advanced, or metastatic
Treatment Options for Pancreatic Cancer
Surgery: The Only Curative Option
Surgical resection remains the only potentially curative treatment for pancreatic cancer. The main surgical procedures include:
- Pancreaticoduodenectomy (Whipple procedure) — for tumors of the pancreatic head, neck, and uncinate process
- Distal pancreatectomy — for tumors of the pancreatic body and tail
- Total pancreatectomy — for tumors involving the entire pancreas
- Vascular resection and reconstruction — for tumors involving the portal vein or superior mesenteric vein, performed at high-volume specialist centers
Only 15–20% of patients present with resectable disease at diagnosis. For borderline resectable cases, neoadjuvant therapy can downstage the tumor to allow surgery.
Neoadjuvant & Conversion Therapy
For borderline resectable or locally advanced pancreatic cancer, neoadjuvant chemotherapy (FOLFIRINOX, gemcitabine + nab-paclitaxel) — sometimes combined with radiation — is used to shrink the tumor before surgery. This approach can convert borderline resectable cases to resectable, and in some locally advanced cases, achieve resectability where surgery was initially not possible.
Adjuvant Chemotherapy
After curative resection, adjuvant chemotherapy (modified FOLFIRINOX or gemcitabine + capecitabine) is standard to reduce recurrence risk and improve long-term survival.
Systemic Therapy for Advanced Disease
- First-line: FOLFIRINOX or gemcitabine + nab-paclitaxel
- BRCA1/2-mutant: Olaparib maintenance after platinum-based chemotherapy
- MSI-H / dMMR: Pembrolizumab
- NTRK fusion: Larotrectinib or entrectinib
- KRAS G12C-mutant: Emerging targeted options (sotorasib, adagrasib)
Proton & Heavy Ion Therapy
For locally advanced pancreatic cancer, proton therapy and carbon ion (heavy ion) therapy offer the ability to deliver high doses of radiation to the tumor with minimal damage to surrounding structures — including the duodenum, stomach, and spinal cord. Shanghai is home to China's premier proton and heavy ion therapy center, offering this advanced modality to patients with locally advanced pancreatic cancer.
Why Choose Shanghai for Pancreatic Cancer Treatment?
- China's highest-volume pancreatic cancer center — Fudan University Cancer Hospital's pancreatic surgery department performs more pancreatic cancer resections than any other center in China
- The "Fudan Standard" of individualized treatment — a pioneering protocol that has extended median post-surgical survival by 40% compared to conventional approaches
- Proton and heavy ion therapy — available at Shanghai's dedicated particle therapy center for locally advanced disease
- Multidisciplinary tumor boards — every complex case reviewed by surgery, medical oncology, radiation oncology, radiology, and pathology
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Yu Xianjun — Fudan University Cancer Hospital
Prof. Yu Xianjun is China's foremost pancreatic cancer surgeon and one of the most experienced pancreatic oncologists in the world, based at Fudan University Shanghai Cancer Center (FUSCC) — China's premier dedicated cancer hospital.
National Leadership
Prof. Yu serves as Chairman of the Pancreatic Cancer Committee of the Chinese Anti-Cancer Association (CACA) — the highest leadership position in pancreatic cancer oncology in China. He built the pancreatic surgery department at Fudan University Cancer Hospital from the ground up, establishing it as the national center of excellence for pancreatic cancer care.
Unmatched Surgical Volume
Prof. Yu performs over 400 pancreatic cancer radical resections per year as primary surgeon — and has completed over 4,000 pancreatic cancer surgeries in his career. This volume places him among the highest-volume pancreatic cancer surgeons in the world. In pancreatic surgery, volume is one of the strongest predictors of outcomes: higher-volume surgeons achieve lower complication rates, lower mortality, and better long-term survival.
The "Fudan Standard": 40% Longer Survival
Prof. Yu's most significant clinical contribution is the development of the "Fudan Standard" of individualized pancreatic cancer treatment — a comprehensive, precision-medicine approach that tailors every aspect of care (surgical technique, perioperative management, adjuvant therapy, and follow-up) to the individual patient's tumor biology and clinical profile. This individualized approach has extended the median post-surgical survival of pancreatic cancer patients by 40% compared to conventional treatment standards — a landmark achievement in a disease where survival improvements of any magnitude are hard-won.
Proton & Heavy Ion Therapy Leadership
Since July 2025, Prof. Yu has also served as President of Shanghai Proton and Heavy Ion Hospital — China's leading particle therapy center. This dual role positions him uniquely to integrate cutting-edge radiation technology into the multidisciplinary management of locally advanced pancreatic cancer, offering patients access to proton and carbon ion therapy as part of a comprehensive treatment plan.
Clinical Expertise
- Pancreaticoduodenectomy (Whipple procedure) — including complex vascular resection and reconstruction
- Distal and total pancreatectomy
- Individualized "Fudan Standard" treatment — precision-medicine approach to pancreatic cancer surgery and perioperative care
- Neoadjuvant and conversion therapy — for borderline resectable and locally advanced disease
- Integration of proton/heavy ion therapy — for locally advanced pancreatic cancer
- Multidisciplinary pancreatic cancer management — leading national MDT protocols
For international patients, Prof. Yu's team offers remote pre-consultation review of CT scans, MRI, CA19-9 levels, and pathology reports, enabling a precise resectability assessment and individualized treatment plan to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Yu Xianjun and the Fudan University Cancer Hospital pancreatic cancer team
- ✅ CT scan, MRI, and pathology translation and remote resectability assessment
- ✅ Second opinion facilitation — especially for patients told their pancreatic cancer is inoperable
- ✅ Hospital admission and surgical scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with pancreatic cancer and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0件のコメント